Abbott Laboratories logo
Abbott Laboratories (ABT)
Compare

Abbott Laboratories (ABT) EV/Assets Ratio: 1.65x

Is Abbott Laboratories’s EV/Assets ratio high or low?

Abbott Laboratories's EV/Assets ratio of 1.65x is 40% below its 5-year average of 2.75x, near the low end of its 5-year range (1.55x–3.55x).

The EV/Assets ratio for Abbott Laboratories (ABT) is 1.65x as of Wednesday, June 10, 2026. It is below its 12-month average by 34.06% (2.50x).

ABT EV/Assets Ratio Chart

ABT EV/Assets Ratio
1.65x-44.26% 1Y
Zoom

ABT Average EV/Assets Ratio Chart

ABT Current vs Average EV/Assets Ratio Chart

ABT EV/Assets Ratio Metrics

EV/ASSETS RATIO

1.65x

EV/ASSETS RATIO AVG TTM

2.50x

EV/ASSETS RATIO AVG 3Y

2.67x

EV/ASSETS RATIO AVG 5Y

2.75x

EV/ASSETS RATIO AVG 10Y

2.44x

EV/ASSETS RATIO AVG 15Y

2.07x

EV/ASSETS RATIO AVG 20Y

1.84x

CURRENT VS TTM AVG

-34.06%

CURRENT VS 3Y AVG

-38.27%

CURRENT VS 5Y AVG

-39.98%

CURRENT VS 10Y AVG

-32.37%

CURRENT VS 15Y AVG

-20.47%

CURRENT VS 20Y AVG

-10.43%

ABT Competitors' EV/Assets Ratio

NAMEMARKET CAPEV/ASSETS RATIOTTM3Y5Y
Abbott Laboratories (ABT)1.65x2.50x2.67x2.75x
Gilead Sciences, Inc. (GILD)$151.21B2.97x3.05x2.44x2.15x
Intuitive Surgical, Inc. (ISRG)$146.44B7.30x8.88x9.09x8.50x
Pfizer Inc. (PFE)$146.36B1.01x1.00x1.03x1.28x
Danaher Corporation (DHR)$130.25B1.72x1.98x2.16x2.26x
Thermo Fisher Scientific Inc. (TMO)$179.45B1.94x2.16x2.33x2.57x
Amgen Inc. (AMGN)$183.75B2.49x2.46x2.27x2.38x
CVS Health Corporation (CVS)$125.16B0.77x0.67x0.63x0.70x
Bristol-Myers Squibb Company (BMY)$114.14B1.72x1.55x1.56x1.64x
Vertex Pharmaceuticals Incorporated (VRTX)$110.77B4.10x4.45x4.69x4.46x

Abbott Laboratories EV/Assets Ratio Formula & Definition

EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Abbott Laboratories EV/Assets Ratio FAQ

What is the EV/Assets ratio for Abbott Laboratories (ABT)?
The EV/Assets ratio for ABT stock is 1.65x.
Is Abbott Laboratories's EV/Assets ratio high or low?
Abbott Laboratories's EV/Assets ratio of 1.65x is 40% below its 5-year average of 2.75x, near the low end of its 5-year range (1.55x–3.55x).
What is the TTM average EV/Assets ratio for Abbott Laboratories (ABT)?
The TTM average EV/Assets ratio for ABT stock is 2.50x.
What is the 3Y average EV/Assets ratio for Abbott Laboratories (ABT)?
The 3Y average EV/Assets ratio for ABT stock is 2.67x.
What is the 5Y average EV/Assets ratio for Abbott Laboratories (ABT)?
The 5Y average EV/Assets ratio for ABT stock is 2.75x.
What is the 10Y average EV/Assets ratio for Abbott Laboratories (ABT)?
The 10Y average EV/Assets ratio for ABT stock is 2.44x.
What is the 15Y average EV/Assets ratio for Abbott Laboratories (ABT)?
The 15Y average EV/Assets ratio for ABT stock is 2.07x.
What is the 20Y average EV/Assets ratio for Abbott Laboratories (ABT)?
The 20Y average EV/Assets ratio for ABT stock is 1.84x.

Abbott Laboratories EV/Assets Ratio History

DATEEV/ASSETS RATIO
2026-06-101.65x
2026-06-091.69x
2026-06-081.68x
2026-06-051.69x
2026-06-041.68x
2026-06-031.62x
2026-06-021.62x
2026-06-011.64x
2026-05-291.60x
2026-05-281.61x
2026-05-271.60x
2026-05-261.62x
2026-05-221.63x
2026-05-211.64x
2026-05-201.64x
2026-05-191.65x
2026-05-181.64x
2026-05-151.58x
2026-05-141.59x
2026-05-131.57x
2026-05-121.58x
2026-05-111.55x
2026-05-081.58x
2026-05-071.62x
2026-05-061.61x
2026-05-051.63x
2026-05-041.63x
2026-05-011.66x
2026-04-301.68x
2026-04-291.69x
2026-04-281.97x
2026-04-271.95x
2026-04-241.91x
2026-04-231.94x
2026-04-221.92x
2026-04-211.94x
2026-04-202.01x
2026-04-172.03x
2026-04-162.00x
2026-04-152.12x
2026-04-142.11x
2026-04-132.10x
2026-04-102.10x
2026-04-092.14x
2026-04-082.16x
2026-04-072.13x
2026-04-062.14x
2026-04-022.15x
2026-04-012.14x
2026-03-312.14x
2026-03-302.13x
2026-03-272.17x
2026-03-262.18x
2026-03-252.19x
2026-03-242.17x
2026-03-232.19x
2026-03-202.20x
2026-03-192.24x
2026-03-182.26x
2026-03-172.31x
2026-03-162.29x
2026-03-132.25x
2026-03-122.25x
2026-03-112.30x
2026-03-102.30x
2026-03-092.35x
2026-03-062.28x
2026-03-052.31x
2026-03-042.35x
2026-03-032.36x
2026-03-022.37x
2026-02-272.42x
2026-02-262.42x
2026-02-252.39x
2026-02-242.38x
2026-02-232.40x
2026-02-202.34x
2026-02-192.40x
2026-02-182.42x
2026-02-172.40x
2026-02-132.41x
2026-02-122.38x
2026-02-112.42x
2026-02-102.40x
2026-02-092.37x
2026-02-062.37x
2026-02-052.33x
2026-02-042.31x
2026-02-032.33x
2026-02-022.34x
2026-01-302.34x
2026-01-292.27x
2026-01-282.27x
2026-01-272.31x
2026-01-262.32x
2026-01-232.30x
2026-01-222.32x
2026-01-212.57x
2026-01-202.58x
2026-01-162.59x
2026-01-152.63x
2026-01-142.66x
2026-01-132.65x
2026-01-122.65x
2026-01-092.68x
2026-01-082.69x
2026-01-072.70x
2026-01-062.72x
2026-01-052.69x
2026-01-022.64x
2025-12-312.67x
2025-12-302.68x
2025-12-292.65x
2025-12-262.66x
2025-12-242.66x
2025-12-232.65x
2025-12-222.67x
2025-12-192.67x
2025-12-182.66x
2025-12-172.70x
2025-12-162.70x
2025-12-152.73x
2025-12-122.67x
2025-12-112.63x
2025-12-102.61x
2025-12-092.58x
2025-12-082.60x
2025-12-052.66x
2025-12-042.67x
2025-12-032.67x
2025-12-022.69x
2025-12-012.72x
2025-11-282.74x
2025-11-262.74x
2025-11-252.72x
2025-11-242.71x
2025-11-212.73x
2025-11-202.64x
2025-11-192.69x
2025-11-182.77x
2025-11-172.77x
2025-11-142.78x
2025-11-132.75x
2025-11-122.74x
2025-11-112.70x
2025-11-102.68x
2025-11-072.69x
2025-11-062.66x
2025-11-052.65x
2025-11-042.68x
2025-11-032.64x
2025-10-312.63x
2025-10-302.65x
2025-10-292.65x
2025-10-282.72x
2025-10-272.73x
2025-10-242.72x
2025-10-232.71x
2025-10-222.74x
2025-10-212.74x
2025-10-202.78x
2025-10-172.76x
2025-10-162.74x
2025-10-152.78x
2025-10-142.86x
2025-10-132.82x
2025-10-102.84x
2025-10-092.86x
2025-10-082.88x
2025-10-072.85x
2025-10-062.87x
2025-10-032.88x
2025-10-022.85x
2025-10-012.86x
2025-09-302.87x
2025-09-292.85x
2025-09-262.86x
2025-09-252.86x
2025-09-242.87x
2025-09-232.91x
2025-09-222.93x
2025-09-192.91x
2025-09-182.88x
2025-09-172.87x
2025-09-162.84x
2025-09-152.81x
2025-09-122.86x
2025-09-112.84x
2025-09-102.77x
2025-09-092.83x
2025-09-082.83x
2025-09-052.85x
2025-09-042.85x
2025-09-032.83x
2025-09-022.82x
2025-08-292.84x
2025-08-282.82x
2025-08-272.82x
2025-08-262.82x
2025-08-252.83x
2025-08-222.84x
2025-08-212.83x
2025-08-202.84x
2025-08-192.81x
2025-08-182.79x
2025-08-152.82x
2025-08-142.77x
2025-08-132.77x
2025-08-122.81x
2025-08-112.82x
2025-08-082.88x
2025-08-072.83x
2025-08-062.81x
2025-08-052.80x
2025-08-042.79x
2025-08-012.73x
2025-07-312.71x
2025-07-302.76x
2025-07-292.83x
2025-07-282.79x
2025-07-252.80x
2025-07-242.78x
2025-07-232.78x
2025-07-222.78x
2025-07-212.75x
2025-07-182.74x
2025-07-172.67x
2025-07-162.91x
2025-07-152.90x
2025-07-142.91x
2025-07-112.91x
2025-07-102.95x
2025-07-092.94x
2025-07-082.94x
2025-07-072.95x
2025-07-032.97x
2025-07-022.96x
2025-07-013.01x
2025-06-303.00x
2025-06-272.97x
2025-06-262.95x
2025-06-253.03x
2025-06-243.04x
2025-06-232.94x
2025-06-202.94x
2025-06-182.92x
2025-06-172.92x
2025-06-162.96x
2025-06-132.99x
2025-06-123.01x
2025-06-112.98x
2025-06-102.96x
2025-06-092.94x
2025-06-062.95x
2025-06-052.96x
2025-06-042.93x
2025-06-032.95x
2025-06-022.95x
2025-05-302.95x
2025-05-292.93x

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Abbott Park, IL
114,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Robert Ford